Literature DB >> 28975984

Levels of HBx, VEGF, and CEACAM1 in HBV-related hepatocellular carcinoma and their correlation with cancer prognosis.

C-S Mao1, H Yin, H-B Ning, Z Peng, K Li, G-Q Ding.   

Abstract

OBJECTIVE: Hepatitis B virus X protein (HBx), vascular endothelial growth factor (VEGF) and carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1), are related to HBV associated hepatocellular carcinoma (HCC). This study recruited HCC patients and employed the SMMC-7721 and L02 liver cell lines, to analyze the expression levels of HBx, VEGF and CEACAM1 in liver cancer and their correlation with the cancer prognosis. PATIENTS AND METHODS: HBV-related HCC patients were recruited from our hospital. Immunohistochemistry (IHC) and Western blotting assay were used to detect the expression of HBx, VEGF and CEACAM1 in liver tissues. Multi-variant analysis and the correlation analysis between HBx, VEGF, CEACAM1 expression and clinical/pathological features of HCC were performed by using the Cox regression analysis.
RESULTS: In HBV-related HCC tissues, positive expression rates of HBx, CEACAM1, and VEGF, were 80%, 50%, and 65%, respectively. In HBx-positive group, positive rate for CEACAM1 and VEGF were 56.25% and 75%, while in HBx-negative group such figures were 75% and 25% (p<0.05). HCC cells had lower expression of CEACAM1 and higher VEGF levels compared to normal hepatocytes. Those HCC cells transfected with HBx had even lower CEACAM1 and higher VEGF levels compared to un-transfected cells. HBx was negatively correlated with CEACAM1 and positively correlated with VEGF. Expressions of these three factors were all independent risk factors as they were correlated with lesion size, venous infiltration, metastasis, and capsule.
CONCLUSIONS: HBx, VEGF and CEACAM1 were widely expressed in HBV-related HCC. HBx may facilitate occurrence and progression of HBV-related HCC via down-regulating CEACAM1 and up-regulating VEGF.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28975984

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development.

Authors:  Arthur T Kopylov; Alexander A Stepanov; Kristina A Malsagova; Deepesh Soni; Nikolay E Kushlinsky; Dmitry V Enikeev; Natalia V Potoldykova; Andrey V Lisitsa; Anna L Kaysheva
Journal:  Molecules       Date:  2020-01-31       Impact factor: 4.411

2.  Ahypoxia-related signature enhances the prediction of the prognosis in hepatocellular carcinoma patients and correlates with sorafenib treatment response.

Authors:  Hong-Ye Jiang; Gang Ning; Yen-Sheng Wang; Wei-Biao Lv
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

3.  Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies.

Authors:  Chia-Jui Yen; Masatoshi Kudo; Ho-Yeong Lim; Chih-Hung Hsu; Arndt Vogel; Giovanni Brandi; Rebecca Cheng; Ioana Simona Nitu; Paolo Abada; Yanzhi Hsu; Andrew X Zhu; Yoon-Koo Kang
Journal:  Liver Cancer       Date:  2020-05-05       Impact factor: 11.740

Review 4.  Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma.

Authors:  Min Yao; Jun-Ling Yang; De-Feng Wang; Li Wang; Ying Chen; Deng-Fu Yao
Journal:  World J Clin Cases       Date:  2022-04-16       Impact factor: 1.534

5.  Dandelion Polysaccharide Exerts Anti-Angiogenesis Effect on Hepatocellular Carcinoma by Regulating VEGF/HIF-1α Expression.

Authors:  Feng Ren; Kaixuan Wu; Yun Yang; Yingying Yang; Yuxia Wang; Jian Li
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810

6.  Establishment of a Cell Culture Model Permissive for Infection by Hepatitis B and C Viruses.

Authors:  Teruhime Otoguro; Tomohisa Tanaka; Hirotake Kasai; Nobuhiro Kobayashi; Atsuya Yamashita; Takasuke Fukuhara; Akihide Ryo; Moto Fukai; Akinobu Taketomi; Yoshiharu Matsuura; Kohji Moriishi
Journal:  Hepatol Commun       Date:  2020-12-19

7.  Serum Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Level in Patients with Hepatocellular Carcinoma.

Authors:  Ekawee Sripariwuth; Setthachai Piwchan; Sutatip Pongcharoen
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

8.  Comprehensive investigation of p53, p21, nm23, and VEGF expression in hepatitis B virus-related hepatocellular carcinoma overall survival after hepatectomy.

Authors:  Guang-Zhi Zhu; Xi-Wen Liao; Xiang-Kun Wang; Yi-Zhen Gong; Xiao-Guang Liu; Long Yu; Chuang-Ye Han; Cheng-Kun Yang; Hao Su; Ke-Tuan Huang; Ting-Dong Yu; Jian-Lu Huang; Jia Li; Zhi-Ming Zeng; Wei Qin; Zheng-Qian Liu; Xin Zhou; Jun-Qi Liu; Lei Lu; Quan-Fa Han; Li-Ming Shang; Xin-Ping Ye; Tao Peng
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

9.  miR-378a-5p improved the prognosis and suppressed the progression of hepatocellular carcinoma by targeting the VEGF pathway.

Authors:  Haibo Zou; Lan Yang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.